Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

  • Who We Are
    • About
    • Mission
    • History
    • Divisions
      • Atlanta
        • Atlanta Leadership
        • Atlanta Contacts
      • Caribbean
        • Caribbean Leadership
        • Caribbean Contacts
      • Chicago
        • Chicago Leadership
        • Chicago Contacts
      • Dallas
        • Dallas Leadership
        • Dallas Contacts
      • Detroit
        • Detroit Leadership
        • Detroit Contacts
      • El Paso
        • El Paso Leadership
        • El Paso Contacts
      • Headquarters
      • Houston
        • Houston Leadership
        • Houston Contacts
      • Los Angeles
        • Los Angeles Leadership
        • Los Angeles Contacts
      • Louisville
        • Louisville Leadership
        • Louisville Contacts
      • Miami
        • Miami Leadership
        • Miami Contacts
      • New England
        • New England Leadership
        • New England Contacts
      • New Jersey
        • New Jersey Contacts
      • New Orleans
        • New Orleans Leadership
        • New Orleans Contacts
      • New York
        • New York Leadership
        • New York Contacts
      • Omaha
        • Omaha Leadership
        • Omaha Contacts
      • Philadelphia
        • Philadelphia Leadership
        • Philadelphia Contacts
      • Phoenix
        • Phoenix Leadership
        • Phoenix Contacts
      • Rocky Mountain
        • Rocky Mountain Contacts
      • San Diego
        • San Diego Leadership
        • San Diego Contacts
      • San Francisco
        • San Francisco Contacts
      • Seattle
        • Seattle Contacts
      • St. Louis
        • St. Louis Leadership
        • St. Louis Contacts
      • Washington, DC
        • Washington Leadership
        • Washington Contacts
    • DEA Museum
    • Foreign Offices
      • Africa
      • Andean
      • Caribbean
      • Europe
      • Far East
      • Middle East
      • North and Central America
      • Southern Cone
    • Operational Divisions
      • Aviation Division
      • Diversion Control Division
    • Wall of Honor
    • Contact Us
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • What We Do
    • Law Enforcement
      • DEA Office of Training
        • Office of Training Programs
      • El Paso Intelligence Center (EPIC)
        • Leadership
        • Mission
        • Services
        • Contacts
      • Forensic Sciences
        • Computer Forensics Program
        • Environmental Management
        • Laboratories
      • Intelligence
      • Operations
        • Administrative Law Judges
        • DEA Asset Forfeiture
        • Domestic Cannabis Suppression / Eradication Program
        • HIDTA
        • OCDETF
        • State and Local Task Forces
    • Education and Prevention
      • DEA’s Family Summit
      • Operation Engage
      • Community Outreach
      • Red Ribbon
        • Kiki and the History of Red Ribbon Week
        • Red Ribbon Toolkit - Resources For Your Community
      • Just Think Twice
      • Campus Drug Prevention
      • Get Smart About Drugs
      • Operation Prevention
    • Drug Information
      • Drug Policy
      • Drug Scheduling
      • The Controlled Substances Act
    • News
      • Alerts
      • Press Releases
      • Most Wanted Fugitives
        • All Fugitives
      • Stories
      • Events
      • Speeches
      • Testimony
    • Campaigns
      • One Pill Can Kill
        • Partner Toolbox
        • Social Media Campaign
      • DEA National Prescription Drug Take Back Day
  • Careers
    • Special Agent
      • Special Agent FAQs
      • Special Agent Job Announcements
    • Diversion Investigator
      • Diversion Investigator Job Announcement
    • Intelligence Research Specialist
      • Intelligence Research Specialist Job Announcements
      • Intelligence Research Specialists FAQs
      • Schedule A Hiring Authority: Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • How to Apply
      • Employment Requirements
      • Equal Opportunity Employer
      • How To Claim Veterans' Preference
      • Priority Consideration
      • Benefits
      • Veterans and People With Disabilities
  • Resources
    • Recovery Resources
    • Data and Statistics
      • Domestic Arrests
      • Staffing and Budget
    • FOIA
      • About FOIA
      • Contact DEA FOIA
      • Make a Request
      • What Happens After Making a Request
      • Requester Categories
      • Fees Charged
      • Fee Waiver
      • FOIA FAQ
      • FOIA Logs and Reports
      • FOIA Library
      • Additional FOIA Links
      • FOIA Exemptions
      • What Are Exclusions?
      • Privacy Act
      • Privacy Act Exemptions
      • Privacy Impact Assessment and Management Information Systems
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
      • Victim Witness Assistance Program Resources

United States Drug Enforcement Administration

  • Search
  • Full Menu

Main Menu

  • Who We Are
  • What We Do
  • Careers
  • Resources
  • Submit A Tip
  • Get Updates
  • Scam Alert
  • English
  • ES

PUBLIC SAFETY ALERT

DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine - DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine

Drug Enforcement Administration

Headquarters
@DEAHQ
February 24, 2023
Contact: Media Relations
Phone Number: (571) 776-2508
For Immediate Release

DEA Announces Proposed Rules for Permanent Telemedicine Flexibilities

DEA extends many telemedicine flexibilities adopted during the COVID-19 PHE with appropriate safeguards

WASHINGTON - Today, the Drug Enforcement Administration announced proposed permanent rules for the prescribing of controlled medications via telemedicine, expanding patient access to critical therapies beyond the scheduled end of the COVID-19 public health emergency. The public will be able to comment for 30 days on the proposed rules.

The proposed rules – developed with the U.S. Department of Health and Human Services and in close coordination with the U.S. Department of Veterans Affairs – propose to extend many of the flexibilities adopted during the public health emergency with appropriate safeguards.

The proposed rules do not affect:

  • Telemedicine consultations that do not involve the prescribing of controlled medications.

  • Telemedicine consultations by a medical practitioner that has previously conducted an in-person medical examination of a patient.

The proposed rules also would not affect:

  • Telemedicine consultations and prescriptions by a medical practitioner to whom a patient has been referred, as long as the referring medical practitioner has previously conducted an in-person medical examination of the patient.

The proposed rules would provide safeguards for a narrow subset of telemedicine consultations—those telemedicine consultations by a medical practitioner that has: never conducted an in-person evaluation of a patient; AND that result in the prescribing of a controlled medication. For these types of consultations, the proposed telemedicine rules would allow medical practitioners to prescribe:

  • a 30-day supply of Schedule III-V non-narcotic controlled medications; 

  • a 30-day supply of buprenorphine for the treatment of opioid use disorder

without an in-person evaluation or referral from a medical practitioner that has conducted an in-person evaluation, as long as the prescription is otherwise consistent with any applicable Federal and State laws. The proposed rules are explained in further detail for patients and medical practitioners on DEA.gov.

“DEA is committed to ensuring that all Americans can access needed medications,” said DEA Administrator Anne Milgram.  “The permanent expansion of telemedicine flexibilities would continue greater access to care for patients across the country, while ensuring the safety of patients. DEA is committed to the expansion of telemedicine with guardrails that prevent the online overprescribing of controlled medications that can cause harm.”

“Improved access to mental health and substance use disorder services through expanded telemedicine flexibilities will save lives,” said HHS Secretary Xavier Becerra. “We still have millions of Americans, particularly those living in rural communities, who face difficulties accessing a doctor or health care provider in-person. At HHS, we are committed to working with our federal partners and stakeholders to advance proven technologies and lifesaving care for the benefit of all Americans.”

The proposed telemedicine rules also further DEA’s goal of expanding access to medication for opioid use disorder to anyone in the country who needs it. “Medication for opioid use disorder helps those who are fighting to overcome substance use disorder by helping people achieve and sustain recovery, and also prevent drug poisonings,” said DEA Administrator Milgram. “The telemedicine regulations would continue to expand access to buprenorphine for patients with opioid use disorder.”

The full text of the proposals may be found here and here. The public has 30 days to review and comment on the proposals, which DEA will then consider before drafting final regulations. DEA is appreciative of the public’s feedback.

For more information on DEA’s continued efforts to expand access to medications used in treatment for those suffering from opioid use disorder, visit: DEA’s Commitment to Expanding Access to Medication-Assisted Treatment.

Additional resources for patients can be found here: 

  • Is My Prescription a Controlled Medication? Controlled-Non Controlled List (dea.gov)

  • Can My Medication be Prescribed through Telemedicine?  Controlled Substance Guidance (dea.gov)

Additional resources for practitioners can be found here:

  • Proposed Rules Summary Telemedicine Rules Summary.pdf (dea.gov)

  • Proposed Rules Highlights for Medical Practitioners Telehealth Practitioner Narrative.pdf (dea.gov)

 

###

The Drug Enforcement Administration encourages that all comments be submitted through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the Web page or to attach a file for lengthier comments.  Please go to http://www.regulations.gov/ and follow the online instructions at that site for submitting comments.

  • Facebook
  • Twitter
  • Email

SAMHSA Behavioral Health Treatment Locator

  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Drug Prevention
    • Law Enforcement
    • Diversion Control Division
    • News
  • Careers
    • Overview
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
  • Resources
    • Drug Information
    • Employee Assistance Program
    • Equal Opportunity Employer
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
  • Policies
    • Accessibility, Plug-ins & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
Home

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook Twitter LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster